Diagnosis of familial dysbetalipoproteinemia due to APOE p.(Arg154Ser): The role of ultracentrifugation and lipid ratios
Journal of Clinical Lipidology · 2026
DOI: 10.1016/j.jacl.2026.05.241 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Clinical Lipidology, 2026. Verfasst von Armando Raul Guerra-Ruiz und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Laboratory Medicine, Hospital Universitario Marqués de Valdecilla, Santander, Spain (Guerra-Ruiz and Lavin Gomez); Instituto de Investiga…. Hauptthemen laut MEDLINE: Hyperlipoproteinemia Type III, Apolipoproteins E, Lipids. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben. Gefördert von: Instituto de Investigacion Marques de Valdecilla.
Abstract (Originalsprache)
Dysbetalipoproteinemia is classically associated with the Apolipoprotein E (APOE) ε2/ε2 genotype. However, rare variants may lead to atypical presentations with dominant inheritance patterns and distinct biochemical profiles. We report a 65-year-old woman with persistent mixed dyslipidemia and intolerance to multiple lipid-lowering therapies. Despite correction of secondary causes, including subclinical hypothyroidism, lipid abnormalities persisted. Advanced lipid testing revealed elevated apolipoprotein B and lipid ratios consistent with remnant lipoprotein accumulation. Density-gradient ultracentrifugation demonstrated cholesterol-enriched very-low-density lipoprotein (VLDL) particles with an increased cholesterol content of VLDL (VLDL-C)/triglyceride ratio (0.38), supporting the diagnosis of dysbetalipoproteinemia. Genetic analysis identified a heterozygous p.(Arg154Ser) variant in the APOE gene, while the APOE genotype was ε3/ε3. Treatment with a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitor led to significant lipid improvement. This case highlights a nonclassical form of dysbetalipoproteinemia associated with a rare APOE variant in the absence of the ε2/ε2 genotype and illustrates a pragmatic, stepwise diagnostic approach integrating accessible biomarkers with specialized testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Laboratory Medicine, Hospital Universitario Marqués de Valdecilla, Santander, Spain (Guerra-Ruiz and Lavin Gomez); Instituto de Investigación Valdecilla (IDIVAL), Santander, Spain (Guerra-Ruiz, Millan, Real…
- Division of Internal Medicine, Hospital Universitario Marqués de Valdecilla, Santander, Spain (Millan and Hernández Hernández); Departamento de Medicina y Psiquiatría, Universidad de Cantabria, Santander, Spain (Hernánd…
- Division of Genetics, Hospital Universitario Marqués de Valdecilla, Santander, Spain (Real Bolt); Instituto de Investigación Valdecilla (IDIVAL), Santander, Spain (Guerra-Ruiz, Millan, Real Bolt, Lavin Gomez, and Hernán…
Förderung
- Instituto de Investigacion Marques de Valdecilla
Zitieren
APA
Guerra-Ruiz, A. R., Millan, M. M., Real Bolt, A. D., Lavin Gomez, B. A., & Hernández Hernández, J. L. (2026). Diagnosis of familial dysbetalipoproteinemia due to APOE p.(Arg154Ser): The role of ultracentrifugation and lipid ratios. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2026.05.241
Vancouver
Guerra-Ruiz AR, Millan MM, Real Bolt AD, Lavin Gomez BA, Hernández Hernández JL. Diagnosis of familial dysbetalipoproteinemia due to APOE p.(Arg154Ser): The role of ultracentrifugation and lipid ratios. Journal of Clinical Lipidology. 2026. doi:10.1016/j.jacl.2026.05.241
BibTeX
@article{GuerraRuiz2026,
author = {Guerra-Ruiz, Armando Raul and Millan, Marta Martin and Real Bolt, Alvaro Del and Lavin Gomez, Bernardo Alio and Hernández Hernández, Jose Luis},
title = {Diagnosis of familial dysbetalipoproteinemia due to APOE p.(Arg154Ser): The role of ultracentrifugation and lipid ratios},
journal = {Journal of Clinical Lipidology},
year = {2026},
doi = {10.1016/j.jacl.2026.05.241}
}
EUVIMED